Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 20/20 | 0.71 |
| ▸ | MAP2K2 | P36507 | 2/20 | 0.47 |
| ▸ | MAP2K5 | Q13163 | 1/20 | 0.43 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4755553 | 0.94 | MAP2K1 (0.70) | MAP2K1MAP2K2 | |
| SCHEMBL4789648 | 0.88 | MAP2K1 (0.71) | MAP2K1MAP2K2 | |
| SCHEMBL16366765 | 0.87 | MAP2K1 (0.55) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL4789765 | 0.86 | MAP2K1 (0.70) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5058386 | 0.83 | MAP2K1 (1.00) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL4788940 | 0.83 | MAP2K1 (0.79) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5063547 | 0.82 | MAP2K1 (0.90) | MAP2K1MAP2K2MAP2K5EIF2AK1 | |
| SCHEMBL5058419 | 0.81 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL5054933 | 0.81 | MAP2K1 (1.00) | MAP2K1 | |
| SCHEMBL5054941 | 0.81 | MAP2K1 (1.00) | MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080312307-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | claimed |
| US-20080312307-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312307-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| US-20080312307-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-18 | — | — | US | disclosed |
| WO-2008148034-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-04 | — | — | WO | disclosed |
| WO-2008148034-A1 | MAPK/ERK KINASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080312307-A1 | MAPK/ERK KINASE INHIBITORS | MAPK1, MAP3K1, MAP3K7 | MAP2K1 45/4885MAP2K2 41/4885MAP2K5 46/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.